Ari Siggaard Knoph from Novo Nordisk shares how the company transitioned from SAS to R for FDA submissions. From early Shiny apps to full-scale open-source workflows, learn how this shift accelerated innovation, attracted top talent, and redefined clinical programming. 

In this episode, you will learn:

• How Novo Nordisk transitioned from legacy systems to R for regulatory submissions
• How Shiny applications became the catalyst for internal buy-in
• How open-source adoption has broadened the company’s talent pool and improved productivity
• Future directions in pharma tech

__________________________________________
More about Appsilon:
► https://www.appsilon.com/
Appsilon empowers pharmaceutical and life sciences companies to leverage open-source technology for faster, data-driven decision-making in regulated environments.
Schedule a free consultation with our expert
► https://www.appsilon.com/contact-us 
__________________________________________
or more insights about how technology helps scientists push the boundaries of data analysis and reporting check out our blog:
► http://appsilon.com/blog 
LinkedIn: https://www.linkedin.com/company/appsilon/